<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02118077</url>
  </required_header>
  <id_info>
    <org_study_id>PC6</org_study_id>
    <nct_id>NCT02118077</nct_id>
  </id_info>
  <brief_title>Sequential Trial of G17DT for the Treatment of Advanced Pancreatic Cancer</brief_title>
  <acronym>PC6</acronym>
  <official_title>A Prospective, Randomized, Double-blind, Placebo-controlled, Group Sequential Trial of G17DT for the Treatment of Advanced Pancreatic Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cancer Advances Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cancer Advances Inc.</source>
  <brief_summary>
    <textblock>
      Compare the effect of G17DT with that of placebo on the survival of subjects with advanced
      pancreatic cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2001</start_date>
  <primary_completion_date type="Actual">April 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient Survival</measure>
    <time_frame>Up to week 134</time_frame>
    <description>The vital status of each patient was followed until death or end of the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Serious and Non-Serious Adverse Events</measure>
    <time_frame>up to week 134</time_frame>
    <description>Adverse events, defined as any event involving adverse reactions, illnesses with onset during the study, or exacerbations of pre-exisiting illnesses, were assessed at each visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective tumor response</measure>
    <time_frame>Weeks 24 and 52</time_frame>
    <description>Patients were monitored for an objective tumor response measured by means of an abdomincal computed tomography.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">154</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>G17DT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>250 µg administered at Weeks 0,1,3 and 24 by intramuscular injection, followed by additional injections (boosters) of 250 µg every 6 months at investigator's discretion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered at Weeks 0, 1, 3, and 24 by intramuscular injection followed by additonal injections of placebo every 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>G17DT</intervention_name>
    <arm_group_label>G17DT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with a histologically or cytologically confirmed diagnosis of pancreatic
             carcinoma, who were not eligible for tumor resection with curative intent (i.e., Stage
             II, III, or IV disease)

          -  Male or female subjects over 18 years of age

          -  Subjects with a life expectancy of at least 2 months

          -  KPS score of ≥60%

          -  Written informed consent

        Exclusion Criteria:

          -  Previous, concomitant, or anticipated use (up to Week 12) of chemotherapy,
             radiotherapy, immunotherapy, or any other anticancer therapy

          -  Previous (during the 4 weeks before the study), concomitant, or anticipated use (up to
             Week 12) of immunosuppressants. However, for systemic [i.e., oral or injected]
             corticosteroids, previous use and concomitant use at study entry were prohibited,
             while introduction during the course of the study was permitted.)

          -  History of other malignant tumor within the previous 5 years, except nonmelanomatous
             skin cancer, and in situ carcinoma of the uterine cervix

          -  Known immunodeficiency

          -  Females who were pregnant, planning to become pregnant, or lactating (Women who, in
             the opinion of the investigator, were of childbearing potential were to have a
             negative pregnancy test before study drug administration.)

          -  Subjects taking part in another study involving an investigational or licensed drug or
             device in the 3 months preceding enrollment or up to Week 12 during this study

          -  Previous G17DT treatment

          -  Hematological indicators as follows:

               -  Hemoglobin &lt;9.5 g/dL

               -  Neutrophils &lt;2.0 × 109/L

               -  Platelets &lt;100 × 109/L

          -  Any other condition or circumstance that might have the following results:

               -  Worsen if the subject participated in the study

               -  Reduce the subject's ability to comply with the protocol

               -  Confound the interpretation of the study results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 16, 2014</study_first_submitted>
  <study_first_submitted_qc>April 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2014</study_first_posted>
  <last_update_submitted>April 17, 2014</last_update_submitted>
  <last_update_submitted_qc>April 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

